SELLAS Life Sciences Group, Inc. (SLS) key performance indicators and operating metrics (2 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Enrolled acute myeloid leukemia patients | 28.00 | FY2026-Q2 |
| New warrant exercise price | 2.00 USD_per_share | FY2025-Q4 |
Back to SLS overview · SLS earnings · SLS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.